The KLRB1 Knockout KYSE-30 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population targeting the KLRB1 gene in the human KYSE-30 esophageal squamous cell carcinoma line. This model provides a heterogeneous loss-of-function system for studying CD161-dependent pathways, capturing a range of gene disruptions across the cell pool.
The host KYSE-30 cell line is an epithelial model derived from a well-differentiated human esophageal squamous cell carcinoma, widely used in esophageal cancer research to investigate tumor cell proliferation, invasiveness, and immune modulation. Its malignant phenotype and epithelial origin make it a pertinent platform for examining the role of immune receptors such as CD161 in esophageal carcinoma.
KLRB1 encodes CD161, a C-type lectin inhibitory receptor that modulates NK and T cell cytotoxicity. Upon binding its ligand LLT1 (CLEC2D), CD161 recruits the tyrosine phosphatases SHP-1 (PTPN6) and SHP-2 (PTPN11), which dephosphorylate proximal kinases LCK and ZAP70, attenuating activation signals. This cascade leads to suppression of transcription factors NFAT and AP-1, thereby fine-tuning cytokine production and cytotoxic responses. Inflammatory cytokines such as IL-12 and IL-15 can upregulate KLRB1, integrating innate immune cues with inhibitory checkpoint pathways.
In the KYSE-30 esophageal cancer context, KLRB1 knockout abrogates CD161-mediated inhibitory signaling, potentially altering tumor cell responsiveness to immune effectors and intrinsic behavior. Researchers can dissect how CD161 loss impacts proliferation, apoptosis, and invasive capacity, as well as investigate tumor-immune cell interactions, including NK cell-mediated killing. This model is invaluable for studying immune evasion tactics of esophageal squamous cell carcinomas and for evaluating CD161 as a novel immunotherapeutic target.
Typical applications include western blotting for CD161, RT-qPCR for KLRB1 transcripts, and flow cytometry to assess surface expression. Functional studies may utilize cell proliferation (MTT) assays, transwell migration/invasion experiments, apoptosis detection via Annexin V staining, and co-culture cytotoxicity assays with primary NK cells. These tools enable investigation of CD161-dependent pathways in esophageal cancer proliferation, immune checkpoint modulation, and drug screening. For further details, please contact Ascent Research.
